Butein

• Description:

  Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4[1]. Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells[2]. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a[3]. Butein is a SIRT1 activator (STAC) .

• Product Name Alternative:

  2’,3,4,4’-tetrahydroxy Chalcone

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Autophagy; EGFR; Phosphodiesterase (PDE)

• Type:

  Natural Products

• Related Pathways:

  Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Butein.html

• Purity:

  99.64

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  OC1=CC=C (C (/C=C/C2=CC (O) =C (O) C=C2) =O) C (O) =C1

• Molecular Formula:

  C15H12O5

• Molecular Weight:

  272.25

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Yu SM, et al. Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor.Eur J Pharmacol. 1995 Jun 23;280 (1) :69-77.|[2]Yang EB, et al. Butein, a specific protein tyrosine kinase inhibitor.Biochem Biophys Res Commun. 1998 Apr 17;245 (2) :435-8.|[3]Zhang L, et al. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.Int J Mol Med. 2015 Oct;36 (4) :957-66.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Natural Products

• Clinical Information:

  No Development Reported

• Isoform:

  EGFR/ErbB1/HER1; PDE4

• CAS Number:

  487-52-5